All Stories

BiomX's bacteria-killing virus reduces diabetic bone ul...

BiomX’s acquisition of Adaptive Phage Therapeutics is looking like a good bet no...

Transcend rises above threshold for success, linking MD...

Transcend Therapeutics has glided over the bar for success, linking its MDMA ana...

Opthea scraps wet AMD program after eye drug loses out ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving...

Exact Sciences kicks off commercial launch of next-gen ...

Cologuard is getting an upgrade after 10 years on the market. Exact Sciences sai...

Lilly links lepodisiran to durably lower lipoprotein in...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular dis...

Vertex abandons islet cell-device combo after failing t...

Vertex is ending work on one of its two islet cell treatments after the diabetes...

RFK Jr. cuts 4,700 FDA and NIH jobs as HHS eliminates '...

The federal government is cutting 3,500 full-time FDA employees and 1,200 NIH wo...

Langer spinout Lyndra Therapeutics begins winding down ...

Lyndra Therapeutics, which spun out of Moderna co-founder Robert Langer’s lab at...

FDA's novel medical device clearances slow to a crawl

According to the FDA’s public database, since the start of this year the agency ...

Candel's lung cancer survival data light path toward pi...

Candel Therapeutics has identified a subpopulation of lung cancer patients livin...

'It's just ugly': Federal funding cuts to Columbia Univ...

Earlier this month, Ian Lipkin, M.D., and his team at Columbia University submit...

Visby Medical nets FDA clearance for completely at-home...

Visby's kit includes vaginal self-collection swabs and a palm-sized, PCR-based t...

Chutes & Ladders—Yet another exec departs CRISPR Tx

CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opp...

Relmada reconsiders phase 2 plans to test magic mushroo...

Relmada Therapeutics’ attempts to see whether a magic mushroom extract could be ...

Fierce Biotech Layoff Tracker 2025: BioAtla implements ...

As always, if you know of layoffs occurring at a biotech, please reach out to th...

What diversity means in medtech

This week on "The Top Line," we hear from Nada Hanafi, co-founder of MedTech Col...

Chutes & Ladders—Yet another exec departs CRISPR

CRISPR Therapeutics’ Julianne Bruno is hitting the exit in favor of external opp...

BioNTech shows off lung cancer survival data behind pha...

BioNTech has shown why it made small cell lung cancer a priority for its PD-L1xV...

Novo inks $1B biobucks Lexicon obesity deal after seein...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attr...

Spero halts development on another antibiotic in latest...

Having stripped back its workforce, antibiotics biotech Spero Therapeutics conti...

BioAtla lays off 30% of staff, hunts out partners for A...

BioAtla is laying off 30% of staff as the biotech searches for partners for some...

Fierce Biotech Layoff Tracker 2025: Nkarta cuts 53 role...

As always, if you know of layoffs occurring at a biotech, please reach out to th...

FDA clears first automated endoscope cleaning system wi...

The FDA has cleared a system designed to clean out the complex inner channels of...

Fierce Biotech Fundraising Tracker '25: Epicrispr claim...

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.